Drugs and patents in ATC class V08CB - Superparamagnetic contrast media

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
GASTROMARK	ferumoxsil
>Tradename	>Generic Name

Last updated: June 13, 2026

Market dynamics and patent landscape for ATC Class V08CB superparamagnetic contrast media

Executive summary. ATC V08CB (superparamagnetic contrast media) is dominated by iron-oxide–based MRI agents, led commercially by products such as ferumoxytol (marketed in the US), ferric carboxymaltose formulations used off-label, and historic/region-specific iron oxide MRI products (eg, ferumoxides). The patent landscape is shaped by: (1) core iron-oxide nanoparticle compositions, (2) carbohydrate/polymer coatings that control colloidal stability and biodistribution, (3) manufacturing and particle-size/process claims, and (4) clinical-use or labeling-related method-of-use positions. Patent term exposure is typically driven by early 2000s filings (with expirations often in the 2020s–2030s), while exclusivity can extend via regulatory data protections and (in some jurisdictions) supplementary protection mechanisms. Litigation risk is concentrated where product families have “follow-on” reformulations or where generics/similar biological products face regulatory classification and physicochemical comparability hurdles.

What superparamagnetic contrast media define ATC V08CB and how is the market segmented?

Featured snippet answer: ATC V08CB covers MRI contrast agents that use superparamagnetic iron oxide nanoparticles to shorten T1 and/or T2 relaxation times, with market segmentation typically by approved active ingredient family (iron-oxide nanoparticles) and by use case (liver/spleen imaging, lymph node imaging, vascular imaging, and off-label applications).

Core modalities within V08CB

V08CB is not a single molecule platform. It is a class defined by contrast behavior and formulation type:

Superparamagnetic iron oxide nanoparticles (SPIONs) with:
- carbohydrate coatings (eg, dextran-derived or carboxymaltose-like moieties),
- polymer or surfactant coatings,
- controlled hydrodynamic size and colloidal stability.
Use case linkage in labeling and clinical practice:
- reticuloendothelial system (RES) imaging (liver, spleen),
- tumor and nodal imaging via nanoparticle uptake,
- angiographic or vascular applications where supported.

Practical market segmentation (commercial behavior)

Commercial dynamics track three repeatable variables:

Regulatory posture by geography
- US: the highest commercial concentration is typically where newer iron-oxide products hold the most durable approvals and where payer coverage is strongest.
- EU/other markets: older iron-oxide agents retain share in certain indications, but competitive pressure increases as patent cliffs near for key compositions and processes.
Hospital procurement and formulary positioning
- MRI contrast agents are purchased based on dosing convenience, batch reliability, and supply assurance, which makes manufacturing/process patents and quality controls commercially relevant.
Clinical adoption and substitution risk
- When particle size distribution and coating chemistry are close among competitors, substitution risk rises.
- Where differences in coating chemistry or hydrodynamic radius materially change biodistribution, payers and clinicians anchor to specific products.

Which companies sell ATC V08CB superparamagnetic contrast media and what is the competitive landscape?

Featured snippet answer: The competitive landscape is centered on companies commercializing iron-oxide MRI agents with patented nanoparticle coatings and manufacturing controls; newer entrants face headwinds around physicochemical comparability, stability specs, and regulatory classification.

Company archetypes

Original developers of specific SPION platforms with protected coatings and particle-size distributions.
Follow-on reformulation developers seeking differentiated dosing, stability, or administration features.
Generic/similar product developers relying on comparability between nanoparticle systems and manufacturing/process validation.

Competitive dynamics by typical product family

Ferumoxytol-type platform (US-heavy)
- Competitive pressure depends on whether products are positioned as MRI agents for vascular or organ imaging and whether dosing paradigms and labeling constrain substitution.
Ferumoxides or other older iron oxide products
- Share can persist where clinical workflows and formularies embed legacy agents, but product modernization and supply chain risk can reshape procurement.

Note: A full company-by-company table with exact current market shares, launches, and patent holdings cannot be produced from the information available in this prompt alone.

What patents protect superparamagnetic contrast media (V08CB) and what claim types dominate?

Featured snippet answer: The patent estate for superparamagnetic contrast media primarily protects nanoparticle compositions of matter (iron-oxide core plus coating chemistry), formulations (concentration, stabilizers, buffers), and manufacturing methods (precipitation, coating attachment, controlled size distribution, sterilization and purification). Secondary claims cover method of use linked to imaging applications.

Dominant claim clusters

1) Composition-of-matter: SPION core and coating chemistry

Typical protected features:

iron oxide polymorph and core crystallinity (magnetite vs maghemite behavior)
coating ligands and their chemical identity
ligand density on the nanoparticle surface
hydrophilic shell composition to limit aggregation in vivo

2) Particle size and size distribution

A recurring pattern in SPION patenting:

claims tied to mean hydrodynamic diameter and distribution windows
claims tied to longitudinal or batch reproducibility of size distribution

3) Colloidal stability in formulation and after administration

Patents often cover:

stabilizers/buffers
pH and ionic strength constraints
limits on aggregation and settling over defined shelf-life conditions

4) Manufacturing processes and in-process controls

Key protected steps:

controlled nucleation and growth during precipitation
coating attachment chemistry and purification
sterile filtration/sterilization methods that preserve size distribution
scale-up controls that maintain lot-to-lot magnetization and relaxivity characteristics

5) Relaxivity and imaging performance metrics

Some estates extend protection to performance parameters:

r1/r2 relaxivity values at defined field strengths
imaging contrast ratios for specific sequences

6) Method-of-use claims

organ-specific or pathway-specific imaging claims
dosing regimen claims (dose, injection rate, timing relative to imaging)

When does exclusivity expire for V08CB superparamagnetic contrast media and how long does protection typically last?

Featured snippet answer: Exclusivity timing is usually driven by (1) patent expiration for composition and method claims and (2) regulatory data protection and market authorization milestones. For iron-oxide MRI products introduced in the early 2000s, patent expirations often fall in the 2020s, with follow-on filings pushing some coverage into the late 2020s or 2030s depending on jurisdiction and patent family strategy.

Typical protection timeline mechanics

Composition/process patents: hard term based on priority date plus filing and prosecution history, with adjustments in some regions.
Regulatory data protection:
- may extend exclusivity for the original marketing authorization holder in the EU framework or via Hatch-Wax-like constructs in jurisdictions with equivalent regimes (depending on regulatory classification).
Supplementary protection mechanisms:
- some jurisdictions provide extensions tied to approval timelines.

A precise “date-by-date” exclusivity calendar for ATC V08CB cannot be produced here without product-specific regulatory and patent record inputs.

What Orange Book status exists for superparamagnetic contrast media and are there Paragraph IV risks?

Featured snippet answer: Orange Book status is product-specific and depends on whether the marketed SPION contrast media have FDA-approved NDA/ANDA listings with unexpired patents and whether challengers file via ANDA pathways. For most SPION products, the main competitive risk arises through similar-product approvals or alternative regulatory pathways rather than classic US “Paragraph IV” dynamics, but any product with Orange Book-listed patents can still face patent challenges.

Paragraph IV and litigation pathway logic

Where US generics compete:

challengers must submit certifications to listed patents.
litigation can follow if patents are asserted and an infringement suit is filed.

Where products are regulated through alternative pathways:

the “similarity” burden can increase, shifting risk toward comparability disputes and labeling differentiation rather than Paragraph IV validity/infringement arguments.

No Orange Book listing details are provided in the prompt, so a real filing-and-patent table cannot be constructed.

Which formulations are protected by patents for superparamagnetic contrast media (V08CB)?

Featured snippet answer: Patents protecting V08CB formulations typically cover coating-stabilized SPION concentrations, buffer/pH systems, tonicity and isotonicity targets, sterility and shelf-life stability, and viscosity or dosing-volume constraints.

Formulation-side differentiators that drive IP

carbohydrate vs polymer coatings
particle concentration (mg Fe/mL) tied to dosing convenience
osmolality targets and pH ranges to limit in vivo aggregation
preservatives (if present) and their compatibility with SPION stability
sterilization method and its effect on nanoparticle size distribution

What method-of-use patents cover imaging with superparamagnetic contrast media?

Featured snippet answer: Method-of-use claims often target imaging indications (organ-specific or pathway-based), dosing timing, injection rates, and imaging sequence timing to maximize contrast while limiting adverse reactions.

Common method-of-use patterns

imaging of lymph nodes using nanoparticle uptake
hepatic and splenic imaging tied to RES clearance kinetics
vascular imaging where supported by labeling and dosing

Litigation sensitivity

Method-of-use protection is more vulnerable than composition/process claims when:

clinical practice changes sequence timing
label changes remove or narrow claimed regimens
competitors design dosing workflows outside the claimed parameters

How strong is the patent estate for V08CB superparamagnetic contrast media?

Featured snippet answer: Strength is usually highest for core nanoparticle composition and coating-related patents that are hard to design around without materially changing physicochemical characteristics. It is lower for:

broad process claims that face prior art and obviousness challenges,
performance-based claims that depend on measurement conditions and are sensitive to claim construction,
method-of-use claims that are limited by how clinicians actually image.

Strength drivers specific to SPIONs

Scientific measurability: particle size distribution and relaxivity create objective anchors, but they also make the claim outcome sensitive to measurement methods.
Design-around feasibility: different coatings can change biodistribution; however, achieving comparable stability and relaxivity without infringement is possible depending on claim scope.
Batch process dependency: manufacturing method claims can be avoided by changing process steps, but that can introduce regulatory and scale-up constraints.

What generic entry risks exist for superparamagnetic contrast media?

Featured snippet answer: Generic entry risk centers on the ability to demonstrate physicochemical comparability (particle size distribution, coating chemistry, relaxivity, colloidal stability) and to meet regulatory requirements for similar performance. IP risk is highest where competitors would use similar coatings and manufacturing processes that read on composition and process claims.

Technical barriers that shape legal risk

demonstration of stable colloidal dispersion across shelf-life
consistency of hydrodynamic diameter and polydispersity index
relaxivity in defined MRI field strengths and sequences
sterility assurance without altering particle properties

Legal barriers that shape technical choices

infringement risk concentrates on:
- coating identity and density,
- size distribution bounds,
- explicit process step parameters.

How does ferumoxytol-type competition compare with older iron-oxide agents?

Featured snippet answer: Ferumoxytol-type newer platforms tend to carry the most durable, modern patent estates around specific coating chemistries and manufacturing controls, while older iron-oxide agents face more competitive substitution as their core composition and process patents age out or become narrower due to claim construction.

Comparison axes that matter in licensing and litigation

coating chemistry differences (design-around opportunities)
hydrodynamic size and distribution (comparability and infringement)
relaxivity profile and imaging sequence fit
stability and dosing differences (clinical adoption and substitution)

What patent litigation affects superparamagnetic contrast media?

Featured snippet answer: Litigation, where it occurs, usually targets infringement of composition/process patents and disputes about comparability and inducement/indirect infringement theories tied to manufacturing and use. The central issue tends to be whether the accused product uses an SPION composition and coating that fall within asserted claim scope and whether the process steps are equivalent.

A specific litigation docket with case numbers, parties, asserted patents, and outcomes cannot be generated from the prompt alone.

What settlement agreements and licensing deals typically look like for V08CB?

Featured snippet answer: Settlements in contrast agent patent disputes usually involve:

delayed launch schedules,
design modifications to avoid specific coating/process claim elements,
royalty or upfront payments under product supply and distribution agreements,
covenants not to sue tied to specific regulatory submissions.

A concrete settlement map requires case and agreement data not included in the prompt.

How do regulatory pathways influence patent challenges and market timing?

Featured snippet answer: Regulatory classification and required comparability studies determine launch timing more than patent mechanics in many SPION cases. If a competitor must run extensive bridging studies, it pushes entry later even when patents expire.

Key pathway mechanics for iron-oxide agents

Data package size: comparability and performance bridging.
Label constraints: whether competitors can claim the same indications and dosing regimen.
Manufacturing changes: process modifications to design around claims often require regulatory re-qualification.

Key data table: what a complete patent-and-timing model should include for V08CB (template)

Layer	What to extract	Why it matters for V08CB
Product	Drug name, strength, dosage form, labeled indications	Determines which patents and exclusivities are relevant
Regulatory	Approval date, reference product link, data protection periods	Sets baseline entry timing
Patent families	Patent numbers, priority dates, assignees, jurisdictions	Defines expiration and claim scope
Claim type	Composition, coating, process, formulation, method-of-use	Determines design-around feasibility
Orange Book / listings	Listed patents and NDA/ANDA linkage (if applicable)	Defines challenge mechanisms in the US
Exclusivity	Regulatory exclusivity periods and any extensions	Adds time beyond patent expiration
Litigation	Case dockets, asserted patents, outcomes, injunctions	Quantifies launch delay risk
Settlement	Agreement terms, launch triggers, covenants	Converts legal uncertainty into scheduled entry

Key Takeaways

V08CB is a nanoparticle IP contest, with composition and coating chemistry plus manufacturing process controls as the most durable protection.
Exclusivity and entry timing are driven by both patent expiration and regulatory pathway requirements for physicochemical and clinical comparability.
Generic/similar entry risks concentrate on whether competitors can match particle size distribution, coating identity/density, and relaxivity without reading on asserted claims.
Litigation and settlements (where they occur) typically resolve around infringement of composition/process patents and around redesign or launch delay.
A decision-ready market and patent view requires product-by-product mapping of approved indications, Orange Book/listing status, patent family expirations by jurisdiction, and any active litigation.

FAQs

How do coating chemistry and particle size distribution influence infringement risk for iron-oxide SPION MRI agents?
What regulatory evidence typically controls “similarity” for superparamagnetic contrast media comparators?
Which patent claim types are easiest to design around in superparamagnetic iron oxide formulations?
How do label indication constraints affect substitution and launch timing for V08CB products?
What data package differences most often delay entry even after patent expiration for SPION contrast media?

References

World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC Classification System: V08CB.
US Food and Drug Administration. Drugs@FDA and Orange Book (Drug Patents and Exclusivity) database.